ClinicalTrials.gg
CompletedNCT06047119GA-TARGETSUpdated Aug 5, 2025

Respiratory and Hemodynamic Targets During General Anesthesia

An interventional study of Blood pressure and Positive end expiratory pressure in Patients Undergoing General Anesthesia, sponsored by Lars Wiuff Andersen. Completed at 6 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Lars Wiuff Andersen · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
485
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This trial is an investigator-initiated, multicenter, randomized, factorial, single-blind trial of multiple hemodynamic and respiratory targets during general anesthesia. These targets include blood pressure, positive end expiratory pressure, tidal volume, and fraction of inspired oxygen. Patients will be randomized to different targets using a factorial design, i.e., each patient is simultaneously randomized to four interventions. There will be five enrolling sites in the Central Denmark Region. 480 high-risk patients will be enrolled.

02

Conditions studied

  • Patients Undergoing General Anesthesia
03

In context

Lead sponsor

Lars Wiuff Andersen is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • (ASA) classification 3 to 5
  • Planned endotracheal intubation with positive pressure ventilation
  • Expected operating time ≥ 90 minutes
  • Certain types of surgery

Exclusion criteria

Exclusion Criteria:

  • Inability to obtain consent (e.g., patient is unconscious, hyperacute surgery)
  • Known or suspected pregnancy
  • Out-patient/same-day surgery
  • Intubated prior to surgery
  • Clinical judgement by the anesthesiologist that any of the interventions could be potentially harmful to the patient
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
485 participants (actual)

Study arms

  • Experimental
    Mean arterial blood pressure above 60 mmHg during general anesthesia and 2 hours after

    Procedure: Blood pressure

  • Experimental
    Mean arterial blood pressure above 70 mmHg during general anesthesia and 2 hours after

    Procedure: Blood pressure

  • Experimental
    Mean arterial blood pressure above 80 mmHg during general anesthesia and 2 hours after

    Procedure: Blood pressure

  • Experimental
    Systolic blood pressure above 90% of baseline during general anesthesia and 2 hours after

    Procedure: Blood pressure

  • Experimental
    Positive end expiratory pressure 5 cm H20 during general anesthesia

    Procedure: Positive end expiratory pressure

  • Experimental
    Positive end expiratory pressure 8 cm H20 during general anesthesia

    Procedure: Positive end expiratory pressure

  • Experimental
    Positive end expiratory pressure 10 cm H20 during general anesthesia

    Procedure: Positive end expiratory pressure

  • Experimental
    Tidal volume 5 ml/kg during general anesthesia

    Procedure: Tidal volume

  • Experimental
    Tidal volume 8 ml/kg during general anesthesia

    Procedure: Tidal volume

  • Experimental
    Tidal volume 10 ml/kg during general anesthesia

    Procedure: Tidal volume

  • Experimental
    Fraction of inspired oxygen 30% during general anesthesia and 2 hours after

    Procedure: Fraction of inspired oxygen

  • Experimental
    Fraction of inspired oxygen 80% during general anesthesia and 2 hours after

    Procedure: Fraction of inspired oxygen

Interventions

  • ProcedureBlood pressure

    Blood pressure targets during general anesthesia and 2 hours after

  • ProcedurePositive end expiratory pressure

    Positive end expiratory pressure during general anesthesia

  • ProcedureTidal volume

    Tidal volume during general anesthesia

  • ProcedureFraction of inspired oxygen

    Fraction of inspired oxygen during general anesthesia and 2 hours after

06

What researchers measure

Primary outcomes

  1. Feasibility: Proportion of eligible patients randomized

    Eligible patients will be defined as those meeting all inclusion criteria and none of the exclusion criteria 1 to 4.

    Time frame: Up to 90 days

  2. Feasibility: Proportion of patient with adherence to the assigned interventions

    Adherence will be defined as follows: The allocated positive end expiratory pressure (± 1 cm H2O), tidal volume (± 1 ml/kg), and FiO2 (± 5%) is used in a minimum of 90% of the randomized patients for the duration of the surgery. Vasopressors/inotropes are only initiated and continued if the blood pressure declines below the allocated target in at least 60% of the patients and at least 60% of time during general anesthesia, i.e., 60% of the registered blood pressures should be within +/- 10 mmHg of the target when vasopressor/inotropes are administered.

    Time frame: During surgery

  3. Feasibility: Proportion of patients with separation of mean arterial pressure

    We aim to achieve at least 5 mmHg separation in mean/median mean arterial pressure for the three blood pressure groups targeting mean arterial pressure.

    Time frame: During surgery

  4. Feasibility: Proportion of patients lost to follow-up

    We aim to obtain data from more than 90% of patients still alive at 30- and 90-days follow-up.

    Time frame: Up to 90 days

Secondary outcomes

  1. Proportion of patients with pulmonary post-operative complications (composite)

    A composite of the following based on European Perioperative Clinical Outcome definitions: Respirator infection, respirator failure, pleural effusion, atelectasis, pneumothorax, bronchospasms, and aspiration pneumonitis.

    Time frame: 30 days

  2. Proportion of patient with pneumonia

    Based on the United States of America Centers for Disease Control and Prevention (CDC) definition of pneumonia

    Time frame: 30 days

  3. Proportion of patient with pulmonary embolism

    Presence of pulmonary embolus on computerized tomography (CT) or magnetic resonance (MR) imaging, or a high probability of pulmonary embolus based on ventilation perfusion scan.

    Time frame: 30 days

  4. Proportion of patient with acute kidney injury

    Composite of post-operative renal complications using Kidney Disease Improving Global Outcomes (KDIGO) criteria

    Time frame: 30 days

  5. Creatinine

    Measured in umol/L

    Time frame: 2 hours after the surgery

  6. Creatinine

    Measured in umol/L

    Time frame: The day after the surgery

  7. Proportion of patient with major adverse cardiac events

    A composite of the following based on European Perioperative Clinical Outcome definitions: Non-fatal cardiac arrest, acute myocardial infarction, congestive heart failure, new cardiac arrhythmia, and angina.

    Time frame: 30 days

  8. Troponin-I

    Measured in ng/L

    Time frame: 2 hours after the surgery

  9. Troponin-I

    Measured in ng/L

    Time frame: The day after the surgery

  10. Proportion of patients with myocardial injury after non-cardiac surgery

    Post-operative troponin-I above the 99% percentile for the respective assay.

    Time frame: 3 days

  11. Alanine transaminase

    Measured in U/L

    Time frame: 2 hours after the surgery

  12. Alanine transaminase

    Measured in U/L

    Time frame: The day after the surgery

  13. Proportion of patients with emergence delirium

    Based on the nursing delirium screening scale to evaluate emergence delirium 90-120 minutes after admission to the post-aesthesia care unit.

    Time frame: 2 hours after the surgery

  14. Proportion of patients with post-operative delirium

    We will categorize delirium as delirium if this is either stated in the medical journal or retrospectively categorized as delirium if it meets pre-defined criteria based on the diagnostic and statistical manual of mental disorders, fifth edition from the American psychiatric association

    Time frame: 7 days

  15. Post-operative pain

    Highest numeric rating scale (NRS) score (from 0 to 10 with higher scores indicating worse pain) documented

    Time frame: 2 hours after the surgery

  16. Opioid administered

    Total opioid administered using morphine equivalent units.

    Time frame: 24 hours

  17. Proportion of patients with post-operative nausea and vomiting

    Highest numeric rating scale (NRS) score (from 0 to 10 with higher scores indicating worse nausea and vomiting) documented

    Time frame: 2 hours after the surgery

  18. Antiemetic treatment

    Administered antiemetic treatment (ondansetron, dexamethasone, cyclizine, droperidol, metoclopramide) within the first 24 hours after the operation.

    Time frame: 24 hours

  19. Proportion of patients with surgical site infections

    Based on the United States of America Centers for Disease Control and Prevention (CDC) definition.

    Time frame: 30 days

  20. Clavien-Dindo grading of complications

    In addition to reporting the individual post-operative complications, we will use the validated Clavien-Dindo classification to grade post-operative complications by the interventions needed.

    Time frame: 30 days

  21. Proportion of patients with intensive care unit admission

    Both planned and unplanned stays at the intensive care unit.

    Time frame: 30 days

  22. Length of hospital stay

    Reported in days.

    Time frame: Up to 90 days

  23. Days alive and out of the hospital

    Reported in days. Patients that die during the 30 days, will receive a value of 0. All admissions at acute care hospitals in Denmark will be included in this outcome.

    Time frame: Within 30 days

  24. Proportion of patients with who die

    Time frame: 30 days

  25. Proportion of patients with who die

    Time frame: 90 days

  26. Health related quality of life

    Based on the EQ-5D-5L questionnaire

    Time frame: 30 days

  27. Health related quality of life

    Based on the EQ-5D-5L questionnaire

    Time frame: 90 days

  28. Proportion of patients with intraoperative complications

    Specific complications occurring during the surgery: Bleeding, need of blood product transfusions, arrhythmia, pneumothorax, cardiac arrest, mortality.

    Time frame: During surgery

  29. Quality of recovery

    Based on the quality of recovery-15 (QoR-15) score. The score ranges from 0-150 with higher scores indicating better recovery.

    Time frame: 30 days

  30. Quality of recovery

    Based on the quality of recovery-15 (QoR-15) score. The score ranges from 0-150 with higher scores indicating better recovery.

    Time frame: 90 days

07

Study locations

6 sites
  • Aalborg University Hospital
    Aalborg, Denmark
  • Aarhus University Hospital
    Aarhus, Denmark
  • Gødstrup Regional Hospital
    Gødstrup, Denmark
  • Horsens Regional Hospital
    Horsens, Denmark
  • Randers Regional Hospital
    Randers, Denmark
  • Viborg Regional Hospital
    Viborg, Denmark
08

References and documents

Publications

  • Hoybye M, Lind PC, Holmberg MJ, Bolther M, Jessen MK, Vallentin MF, Hansen FB, Holst JM, Magnussen A, Hansen NS, Johannsen CM, Enevoldsen J, Jensen TH, Roessler LL, Klitholm MP, Eggertsen MA, Caap P, Boye C, Dabrowski KM, Vormfenne L, Henriksen J, Karlsson M, Balleby IR, Rasmussen MS, Paelestik K, Granfeldt A, Andersen LW. Fraction of inspired oxygen during general anesthesia for non-cardiac surgery: Systematic review and meta-analysis. Acta Anaesthesiol Scand. 2022 Sep;66(8):923-933. doi: 10.1111/aas.14102. Epub 2022 Jun 23. PubMed 35675085 ↗
  • Bolther M, Henriksen J, Holmberg MJ, Jessen MK, Vallentin MF, Hansen FB, Holst JM, Magnussen A, Hansen NS, Johannsen CM, Enevoldsen J, Jensen TH, Roessler LL, Caroe Lind P, Klitholm MP, Eggertsen MA, Caap P, Boye C, Dabrowski KM, Vormfenne L, Hoybye M, Karlsson M, Balleby IR, Rasmussen MS, Paelestik K, Granfeldt A, Andersen LW. Ventilation Strategies During General Anesthesia for Noncardiac Surgery: A Systematic Review and Meta-Analysis. Anesth Analg. 2022 Nov 1;135(5):971-985. doi: 10.1213/ANE.0000000000006106. Epub 2022 Oct 21. PubMed 35703253 ↗
  • Bolther M, Henriksen J, Holmberg MJ, Granfeldt A, Andersen LW. Blood pressure targets during general anaesthesia for noncardiac surgery: A systematic review of clinical trials. Eur J Anaesthesiol. 2022 Nov 1;39(11):903-905. doi: 10.1097/EJA.0000000000001703. Epub 2022 Jul 5. No abstract available. PubMed 35797424 ↗
  • Holst JM, Klitholm MP, Henriksen J, Vallentin MF, Jessen MK, Bolther M, Holmberg MJ, Hoybye M, Lind PC, Granfeldt A, Andersen LW. Intraoperative respiratory and hemodynamic strategies for reducing nausea, vomiting, and pain after surgery: Systematic review and meta-analysis. Acta Anaesthesiol Scand. 2022 Oct;66(9):1051-1060. doi: 10.1111/aas.14127. Epub 2022 Aug 22. PubMed 35924389 ↗

Individual participant data

Plan to share: Yes — Six months after the publication of the last results, all de-identified individual patient data will be made available for data sharing. Procedures, including re-coding of key variables, will be put in place to allow for complete de-identification of the data. Data will be completely anonymized according to Danish law. All relevant trial-related documents, including the protocol, data dictionary, and the main statistical code, will be shared along with the data. There will be no predetermined end date for the data sharing.

Supporting information: Study protocol

Access criteria: Data will be available for any research purpose to all interested parties who have approval from an independent review committee and who have a methodological sound proposal as determined by the steering committee of the current trial. Only the methodological qualities and not the purpose or objective of the proposal will be considered. Interested parties will be able to request the data by contacting the principal investigator. Authorship of publications emerging from the shared data will follow standard authorship guidelines from the International Committee of Medical Journal Editors and might or might not include authors from the steering committee depending on the nature of their involvement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Apr 2025, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2023
First posted
Sep 21, 2023
StartActual
Oct 9, 2023
Primary completionActual
Apr 24, 2025
CompletionActual
Apr 24, 2025
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06047119
Lead sponsor
Lars Wiuff Andersen
Responsible party
Lars Wiuff Andersen (Associate Professor, Aarhus University Hospital) — Sponsor-investigator
First posted
Sep 21, 2023
Start date
Oct 9, 2023
Primary completion
Apr 24, 2025
Completion
Apr 24, 2025
Last update
Aug 5, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion